Advertisement
Australia markets open in 26 minutes
  • ALL ORDS

    8,076.70
    +11.20 (+0.14%)
     
  • AUD/USD

    0.6580
    -0.0002 (-0.03%)
     
  • ASX 200

    7,804.50
    +11.20 (+0.14%)
     
  • OIL

    79.24
    +0.25 (+0.32%)
     
  • GOLD

    2,316.10
    -6.20 (-0.27%)
     
  • Bitcoin AUD

    92,664.03
    -2,245.00 (-2.37%)
     
  • CMC Crypto 200

    1,302.12
    +7.45 (+0.58%)
     

How This Pharma Company Can Benefit From Its Competitors

How This Pharma Company Can Benefit From Its Competitors

The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.